We hypothesize that direct oral anticoagulants, i.e., FXa inhibitors, may have beneficial effects on the mobilization and differentiation of EPCs and may therefore be a powerful treatment method in patients who have coronary artery disease and atrial fibrillation. This evidence concerns the gene F10 and atrial fibrillation.